Cybin Inc.
Cybin Inc. (CYBN.NE) Stock Competitors & Peer Comparison
See (CYBN.NE) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CYBN.NE | CA$6.05 | -3.66% | 145.5M | -1.16 | -CA$5.17 | N/A |
| BLU.TO | CA$19.48 | -0.10% | 2.5B | -20.29 | -CA$0.96 | N/A |
| MMED.NE | CA$14.90 | +9.48% | 1.1B | -4.50 | -CA$3.31 | N/A |
| DRUG.CN | CA$95.41 | -1.75% | 740.5M | -34.57 | -CA$2.76 | N/A |
| EPRX.TO | CA$9.30 | -0.11% | 334.2M | -6.55 | -CA$1.42 | N/A |
| FRX.TO | CA$8.00 | -3.96% | 238.1M | -17.35 | -CA$0.48 | N/A |
| HBP.TO | CA$1.94 | +5.43% | 148.2M | -32.33 | -CA$0.06 | N/A |
| ONC.TO | CA$1.42 | +2.16% | 142.3M | -3.84 | -CA$0.37 | N/A |
| MSCL.TO | CA$8.40 | -2.44% | 127.4M | 2.32 | CA$3.55 | N/A |
| MSET.CN | CA$0.74 | -1.33% | 75M | -12.33 | -CA$0.06 | N/A |
Stock Comparison
CYBN.NE vs BLU.TO Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, BLU.TO has a market cap of 2.5B. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while BLU.TO trades at CA$19.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas BLU.TO's P/E ratio is -20.29. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to BLU.TO's ROE of -0.22%. Regarding short-term risk, CYBN.NE is more volatile compared to BLU.TO. This indicates potentially higher risk in terms of short-term price fluctuations for CYBN.NE.Check BLU.TO's competition here
CYBN.NE vs MMED.NE Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, MMED.NE has a market cap of 1.1B. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while MMED.NE trades at CA$14.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas MMED.NE's P/E ratio is -4.50. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to MMED.NE's ROE of -0.50%. Regarding short-term risk, CYBN.NE is less volatile compared to MMED.NE. This indicates potentially lower risk in terms of short-term price fluctuations for CYBN.NE.Check MMED.NE's competition here
CYBN.NE vs DRUG.CN Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, DRUG.CN has a market cap of 740.5M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while DRUG.CN trades at CA$95.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas DRUG.CN's P/E ratio is -34.57. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to DRUG.CN's ROE of -0.28%. Regarding short-term risk, CYBN.NE is less volatile compared to DRUG.CN. This indicates potentially lower risk in terms of short-term price fluctuations for CYBN.NE.Check DRUG.CN's competition here
CYBN.NE vs EPRX.TO Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, EPRX.TO has a market cap of 334.2M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while EPRX.TO trades at CA$9.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas EPRX.TO's P/E ratio is -6.55. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to EPRX.TO's ROE of -0.66%. Regarding short-term risk, CYBN.NE is more volatile compared to EPRX.TO. This indicates potentially higher risk in terms of short-term price fluctuations for CYBN.NE.Check EPRX.TO's competition here
CYBN.NE vs FRX.TO Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, FRX.TO has a market cap of 238.1M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while FRX.TO trades at CA$8.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas FRX.TO's P/E ratio is -17.35. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to FRX.TO's ROE of -2.36%. Regarding short-term risk, CYBN.NE is more volatile compared to FRX.TO. This indicates potentially higher risk in terms of short-term price fluctuations for CYBN.NE.Check FRX.TO's competition here
CYBN.NE vs HBP.TO Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, HBP.TO has a market cap of 148.2M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while HBP.TO trades at CA$1.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas HBP.TO's P/E ratio is -32.33. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to HBP.TO's ROE of -0.37%. Regarding short-term risk, CYBN.NE is less volatile compared to HBP.TO. This indicates potentially lower risk in terms of short-term price fluctuations for CYBN.NE.Check HBP.TO's competition here
CYBN.NE vs ONC.TO Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, ONC.TO has a market cap of 142.3M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while ONC.TO trades at CA$1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas ONC.TO's P/E ratio is -3.84. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to ONC.TO's ROE of -4.40%. Regarding short-term risk, CYBN.NE is more volatile compared to ONC.TO. This indicates potentially higher risk in terms of short-term price fluctuations for CYBN.NE.Check ONC.TO's competition here
CYBN.NE vs MSCL.TO Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, MSCL.TO has a market cap of 127.4M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while MSCL.TO trades at CA$8.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas MSCL.TO's P/E ratio is 2.32. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to MSCL.TO's ROE of -0.73%. Regarding short-term risk, CYBN.NE is less volatile compared to MSCL.TO. This indicates potentially lower risk in terms of short-term price fluctuations for CYBN.NE.Check MSCL.TO's competition here
CYBN.NE vs MSET.CN Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, MSET.CN has a market cap of 75M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while MSET.CN trades at CA$0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas MSET.CN's P/E ratio is -12.33. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to MSET.CN's ROE of -3.16%. Regarding short-term risk, Volatility data is not available for a full comparison. CYBN.NE has daily volatility of 6.14 and MSET.CN has daily volatility of N/A.Check MSET.CN's competition here
CYBN.NE vs SVA.TO Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, SVA.TO has a market cap of 53.9M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while SVA.TO trades at CA$0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas SVA.TO's P/E ratio is -3.87. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to SVA.TO's ROE of +0.52%. Regarding short-term risk, CYBN.NE is less volatile compared to SVA.TO. This indicates potentially lower risk in terms of short-term price fluctuations for CYBN.NE.Check SVA.TO's competition here
CYBN.NE vs PMN.TO Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, PMN.TO has a market cap of 51.5M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while PMN.TO trades at CA$6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas PMN.TO's P/E ratio is -1.78. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to PMN.TO's ROE of -5.57%. Regarding short-term risk, CYBN.NE is less volatile compared to PMN.TO. This indicates potentially lower risk in terms of short-term price fluctuations for CYBN.NE.Check PMN.TO's competition here
CYBN.NE vs MDNA.TO Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, MDNA.TO has a market cap of 41.9M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while MDNA.TO trades at CA$0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas MDNA.TO's P/E ratio is -4.07. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to MDNA.TO's ROE of -1.04%. Regarding short-term risk, CYBN.NE is less volatile compared to MDNA.TO. This indicates potentially lower risk in terms of short-term price fluctuations for CYBN.NE.Check MDNA.TO's competition here
CYBN.NE vs IGX.TO Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, IGX.TO has a market cap of 41.9M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while IGX.TO trades at CA$0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas IGX.TO's P/E ratio is -3.00. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to IGX.TO's ROE of +1.27%. Regarding short-term risk, CYBN.NE is less volatile compared to IGX.TO. This indicates potentially lower risk in terms of short-term price fluctuations for CYBN.NE.Check IGX.TO's competition here
CYBN.NE vs MBX.TO Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, MBX.TO has a market cap of 31.9M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while MBX.TO trades at CA$0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas MBX.TO's P/E ratio is -7.67. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to MBX.TO's ROE of -0.15%. Regarding short-term risk, CYBN.NE is more volatile compared to MBX.TO. This indicates potentially higher risk in terms of short-term price fluctuations for CYBN.NE.Check MBX.TO's competition here
CYBN.NE vs RVX.TO Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, RVX.TO has a market cap of 31.6M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while RVX.TO trades at CA$0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas RVX.TO's P/E ratio is -2.75. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to RVX.TO's ROE of +0.08%. Regarding short-term risk, CYBN.NE is less volatile compared to RVX.TO. This indicates potentially lower risk in terms of short-term price fluctuations for CYBN.NE.Check RVX.TO's competition here
CYBN.NE vs DTC.CN Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, DTC.CN has a market cap of 31M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while DTC.CN trades at CA$0.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas DTC.CN's P/E ratio is -6.75. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to DTC.CN's ROE of +4.22%. Regarding short-term risk, CYBN.NE is more volatile compared to DTC.CN. This indicates potentially higher risk in terms of short-term price fluctuations for CYBN.NE.Check DTC.CN's competition here
CYBN.NE vs ONCO.CN Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, ONCO.CN has a market cap of 26M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while ONCO.CN trades at CA$0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas ONCO.CN's P/E ratio is -60.00. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to ONCO.CN's ROE of -2.29%. Regarding short-term risk, CYBN.NE is more volatile compared to ONCO.CN. This indicates potentially higher risk in terms of short-term price fluctuations for CYBN.NE.Check ONCO.CN's competition here
CYBN.NE vs AEZS.TO Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, AEZS.TO has a market cap of 25.4M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while AEZS.TO trades at CA$8.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas AEZS.TO's P/E ratio is -2.61. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to AEZS.TO's ROE of -0.13%. Regarding short-term risk, CYBN.NE is less volatile compared to AEZS.TO. This indicates potentially lower risk in terms of short-term price fluctuations for CYBN.NE.Check AEZS.TO's competition here
CYBN.NE vs TELI.CN Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, TELI.CN has a market cap of 23.7M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while TELI.CN trades at CA$0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas TELI.CN's P/E ratio is -10.88. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to TELI.CN's ROE of -1.13%. Regarding short-term risk, CYBN.NE is less volatile compared to TELI.CN. This indicates potentially lower risk in terms of short-term price fluctuations for CYBN.NE.Check TELI.CN's competition here
CYBN.NE vs REUN.TO Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, REUN.TO has a market cap of 16.6M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while REUN.TO trades at CA$1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas REUN.TO's P/E ratio is -0.43. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to REUN.TO's ROE of -1.10%. Regarding short-term risk, CYBN.NE is more volatile compared to REUN.TO. This indicates potentially higher risk in terms of short-term price fluctuations for CYBN.NE.Check REUN.TO's competition here
CYBN.NE vs BLAB.CN Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, BLAB.CN has a market cap of 14.6M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while BLAB.CN trades at CA$0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas BLAB.CN's P/E ratio is 1.50. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to BLAB.CN's ROE of +2.40%. Regarding short-term risk, CYBN.NE is more volatile compared to BLAB.CN. This indicates potentially higher risk in terms of short-term price fluctuations for CYBN.NE.Check BLAB.CN's competition here
CYBN.NE vs DOSE.CN Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, DOSE.CN has a market cap of 14.5M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while DOSE.CN trades at CA$0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas DOSE.CN's P/E ratio is -5.50. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to DOSE.CN's ROE of +0.76%. Regarding short-term risk, CYBN.NE is less volatile compared to DOSE.CN. This indicates potentially lower risk in terms of short-term price fluctuations for CYBN.NE.Check DOSE.CN's competition here
CYBN.NE vs IMV.TO Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, IMV.TO has a market cap of 13.1M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while IMV.TO trades at CA$1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas IMV.TO's P/E ratio is -0.18. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to IMV.TO's ROE of -4.95%. Regarding short-term risk, CYBN.NE is more volatile compared to IMV.TO. This indicates potentially higher risk in terms of short-term price fluctuations for CYBN.NE.Check IMV.TO's competition here
CYBN.NE vs PREV.CN Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, PREV.CN has a market cap of 11.7M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while PREV.CN trades at CA$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas PREV.CN's P/E ratio is -2.00. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to PREV.CN's ROE of +0.43%. Regarding short-term risk, CYBN.NE is more volatile compared to PREV.CN. This indicates potentially higher risk in terms of short-term price fluctuations for CYBN.NE.Check PREV.CN's competition here
CYBN.NE vs MDMA.CN Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, MDMA.CN has a market cap of 11.4M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while MDMA.CN trades at CA$0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas MDMA.CN's P/E ratio is -5.25. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to MDMA.CN's ROE of -0.79%. Regarding short-term risk, CYBN.NE is less volatile compared to MDMA.CN. This indicates potentially lower risk in terms of short-term price fluctuations for CYBN.NE.Check MDMA.CN's competition here
CYBN.NE vs BETR.CN Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, BETR.CN has a market cap of 10.6M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while BETR.CN trades at CA$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas BETR.CN's P/E ratio is -7.00. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to BETR.CN's ROE of +0.19%. Regarding short-term risk, CYBN.NE is less volatile compared to BETR.CN. This indicates potentially lower risk in terms of short-term price fluctuations for CYBN.NE.Check BETR.CN's competition here
CYBN.NE vs BCT.TO Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, BCT.TO has a market cap of 10.6M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while BCT.TO trades at CA$5.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas BCT.TO's P/E ratio is -0.28. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to BCT.TO's ROE of -2.06%. Regarding short-term risk, CYBN.NE is less volatile compared to BCT.TO. This indicates potentially lower risk in terms of short-term price fluctuations for CYBN.NE.Check BCT.TO's competition here
CYBN.NE vs TBP.TO Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, TBP.TO has a market cap of 10.6M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while TBP.TO trades at CA$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas TBP.TO's P/E ratio is -0.31. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to TBP.TO's ROE of -4.68%. Regarding short-term risk, CYBN.NE is more volatile compared to TBP.TO. This indicates potentially higher risk in terms of short-term price fluctuations for CYBN.NE.Check TBP.TO's competition here
CYBN.NE vs GLOW.CN Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, GLOW.CN has a market cap of 10M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while GLOW.CN trades at CA$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas GLOW.CN's P/E ratio is -2.75. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to GLOW.CN's ROE of -0.96%. Regarding short-term risk, CYBN.NE is more volatile compared to GLOW.CN. This indicates potentially higher risk in terms of short-term price fluctuations for CYBN.NE.Check GLOW.CN's competition here
CYBN.NE vs MCUR.CN Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, MCUR.CN has a market cap of 7M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while MCUR.CN trades at CA$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas MCUR.CN's P/E ratio is -0.75. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to MCUR.CN's ROE of -1.61%. Regarding short-term risk, CYBN.NE is more volatile compared to MCUR.CN. This indicates potentially higher risk in terms of short-term price fluctuations for CYBN.NE.Check MCUR.CN's competition here
CYBN.NE vs COOL.CN Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, COOL.CN has a market cap of 6.8M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while COOL.CN trades at CA$0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas COOL.CN's P/E ratio is -1.32. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to COOL.CN's ROE of -2.90%. Regarding short-term risk, CYBN.NE is more volatile compared to COOL.CN. This indicates potentially higher risk in terms of short-term price fluctuations for CYBN.NE.Check COOL.CN's competition here
CYBN.NE vs PHRM.CN Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, PHRM.CN has a market cap of 6.8M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while PHRM.CN trades at CA$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas PHRM.CN's P/E ratio is -3.75. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to PHRM.CN's ROE of -1.67%. Regarding short-term risk, CYBN.NE is more volatile compared to PHRM.CN. This indicates potentially higher risk in terms of short-term price fluctuations for CYBN.NE.Check PHRM.CN's competition here
CYBN.NE vs TRYP.CN Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, TRYP.CN has a market cap of 5.8M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while TRYP.CN trades at CA$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas TRYP.CN's P/E ratio is -1.50. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to TRYP.CN's ROE of +4.03%. Regarding short-term risk, CYBN.NE is more volatile compared to TRYP.CN. This indicates potentially higher risk in terms of short-term price fluctuations for CYBN.NE.Check TRYP.CN's competition here
CYBN.NE vs APS.TO Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, APS.TO has a market cap of 5.7M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while APS.TO trades at CA$2.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas APS.TO's P/E ratio is 2.37. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to APS.TO's ROE of +1.69%. Regarding short-term risk, CYBN.NE is more volatile compared to APS.TO. This indicates potentially higher risk in terms of short-term price fluctuations for CYBN.NE.Check APS.TO's competition here
CYBN.NE vs CMND.CN Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, CMND.CN has a market cap of 5.1M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while CMND.CN trades at CA$1.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas CMND.CN's P/E ratio is -0.04. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to CMND.CN's ROE of +44.20%. Regarding short-term risk, CYBN.NE is more volatile compared to CMND.CN. This indicates potentially higher risk in terms of short-term price fluctuations for CYBN.NE.Check CMND.CN's competition here
CYBN.NE vs GTTX.CN Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, GTTX.CN has a market cap of 4.6M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while GTTX.CN trades at CA$0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas GTTX.CN's P/E ratio is -12.00. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to GTTX.CN's ROE of -0.43%. Regarding short-term risk, CYBN.NE is more volatile compared to GTTX.CN. This indicates potentially higher risk in terms of short-term price fluctuations for CYBN.NE.Check GTTX.CN's competition here
CYBN.NE vs GLAB.CN Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, GLAB.CN has a market cap of 4.6M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while GLAB.CN trades at CA$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas GLAB.CN's P/E ratio is -1.50. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to GLAB.CN's ROE of +0.62%. Regarding short-term risk, CYBN.NE is more volatile compared to GLAB.CN. This indicates potentially higher risk in terms of short-term price fluctuations for CYBN.NE.Check GLAB.CN's competition here
CYBN.NE vs AWKN.NE Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, AWKN.NE has a market cap of 3.9M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while AWKN.NE trades at CA$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas AWKN.NE's P/E ratio is -0.36. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to AWKN.NE's ROE of -4.29%. Regarding short-term risk, CYBN.NE is more volatile compared to AWKN.NE. This indicates potentially higher risk in terms of short-term price fluctuations for CYBN.NE.Check AWKN.NE's competition here
CYBN.NE vs CSCI.TO Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, CSCI.TO has a market cap of 3.9M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while CSCI.TO trades at CA$1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas CSCI.TO's P/E ratio is -0.27. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to CSCI.TO's ROE of -0.13%. Regarding short-term risk, CYBN.NE is less volatile compared to CSCI.TO. This indicates potentially lower risk in terms of short-term price fluctuations for CYBN.NE.Check CSCI.TO's competition here
CYBN.NE vs HEAL.CN Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, HEAL.CN has a market cap of 3.5M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while HEAL.CN trades at CA$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas HEAL.CN's P/E ratio is -1.90. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to HEAL.CN's ROE of +41.60%. Regarding short-term risk, CYBN.NE is more volatile compared to HEAL.CN. This indicates potentially higher risk in terms of short-term price fluctuations for CYBN.NE.Check HEAL.CN's competition here
CYBN.NE vs ASEP.CN Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, ASEP.CN has a market cap of 3.4M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while ASEP.CN trades at CA$0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas ASEP.CN's P/E ratio is -0.32. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to ASEP.CN's ROE of -0.59%. Regarding short-term risk, CYBN.NE is more volatile compared to ASEP.CN. This indicates potentially higher risk in terms of short-term price fluctuations for CYBN.NE.Check ASEP.CN's competition here
CYBN.NE vs MYND.CN Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, MYND.CN has a market cap of 3.3M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while MYND.CN trades at CA$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas MYND.CN's P/E ratio is -3.50. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to MYND.CN's ROE of +0.36%. Regarding short-term risk, CYBN.NE is less volatile compared to MYND.CN. This indicates potentially lower risk in terms of short-term price fluctuations for CYBN.NE.Check MYND.CN's competition here
CYBN.NE vs IPCI.TO Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, IPCI.TO has a market cap of 2.6M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while IPCI.TO trades at CA$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas IPCI.TO's P/E ratio is -0.67. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to IPCI.TO's ROE of +0.31%. Regarding short-term risk, CYBN.NE is less volatile compared to IPCI.TO. This indicates potentially lower risk in terms of short-term price fluctuations for CYBN.NE.Check IPCI.TO's competition here
CYBN.NE vs APLI.TO Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, APLI.TO has a market cap of 2.6M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while APLI.TO trades at CA$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas APLI.TO's P/E ratio is -1.00. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to APLI.TO's ROE of +0.20%. Regarding short-term risk, CYBN.NE is more volatile compared to APLI.TO. This indicates potentially higher risk in terms of short-term price fluctuations for CYBN.NE.Check APLI.TO's competition here
CYBN.NE vs MOOD.CN Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, MOOD.CN has a market cap of 2.5M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while MOOD.CN trades at CA$0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas MOOD.CN's P/E ratio is -3.93. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to MOOD.CN's ROE of -0.63%. Regarding short-term risk, CYBN.NE is more volatile compared to MOOD.CN. This indicates potentially higher risk in terms of short-term price fluctuations for CYBN.NE.Check MOOD.CN's competition here
CYBN.NE vs BIOV.CN Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, BIOV.CN has a market cap of 2M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while BIOV.CN trades at CA$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas BIOV.CN's P/E ratio is -0.29. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to BIOV.CN's ROE of +2.41%. Regarding short-term risk, CYBN.NE is less volatile compared to BIOV.CN. This indicates potentially lower risk in terms of short-term price fluctuations for CYBN.NE.Check BIOV.CN's competition here
CYBN.NE vs AGN.CN Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, AGN.CN has a market cap of 1.8M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while AGN.CN trades at CA$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas AGN.CN's P/E ratio is -0.71. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to AGN.CN's ROE of -0.93%. Regarding short-term risk, CYBN.NE is more volatile compared to AGN.CN. This indicates potentially higher risk in terms of short-term price fluctuations for CYBN.NE.Check AGN.CN's competition here
CYBN.NE vs BRAX.CN Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, BRAX.CN has a market cap of 1.4M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while BRAX.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas BRAX.CN's P/E ratio is -0.10. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to BRAX.CN's ROE of -2.49%. Regarding short-term risk, CYBN.NE is more volatile compared to BRAX.CN. This indicates potentially higher risk in terms of short-term price fluctuations for CYBN.NE.Check BRAX.CN's competition here
CYBN.NE vs ENBI.CN Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, ENBI.CN has a market cap of 1.4M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while ENBI.CN trades at CA$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas ENBI.CN's P/E ratio is -3.33. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to ENBI.CN's ROE of -0.79%. Regarding short-term risk, CYBN.NE is more volatile compared to ENBI.CN. This indicates potentially higher risk in terms of short-term price fluctuations for CYBN.NE.Check ENBI.CN's competition here
CYBN.NE vs HAVN.CN Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, HAVN.CN has a market cap of 1.2M. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while HAVN.CN trades at CA$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas HAVN.CN's P/E ratio is -0.01. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to HAVN.CN's ROE of -2.75%. Regarding short-term risk, CYBN.NE is more volatile compared to HAVN.CN. This indicates potentially higher risk in terms of short-term price fluctuations for CYBN.NE.Check HAVN.CN's competition here
CYBN.NE vs CHGX.CN Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, CHGX.CN has a market cap of 415.6K. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while CHGX.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas CHGX.CN's P/E ratio is -0.50. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to CHGX.CN's ROE of +0.19%. Regarding short-term risk, CYBN.NE is more volatile compared to CHGX.CN. This indicates potentially higher risk in terms of short-term price fluctuations for CYBN.NE.Check CHGX.CN's competition here
CYBN.NE vs CURE.CN Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, CURE.CN has a market cap of 408K. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while CURE.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas CURE.CN's P/E ratio is 0.17. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to CURE.CN's ROE of -0.17%. Regarding short-term risk, CYBN.NE is more volatile compared to CURE.CN. This indicates potentially higher risk in terms of short-term price fluctuations for CYBN.NE.Check CURE.CN's competition here
CYBN.NE vs ABRT.CN Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, ABRT.CN has a market cap of 372.1K. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while ABRT.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas ABRT.CN's P/E ratio is -0.10. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to ABRT.CN's ROE of +16.27%. Regarding short-term risk, CYBN.NE is more volatile compared to ABRT.CN. This indicates potentially higher risk in terms of short-term price fluctuations for CYBN.NE.Check ABRT.CN's competition here
CYBN.NE vs NIRV.CN Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, NIRV.CN has a market cap of 337.6K. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while NIRV.CN trades at CA$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas NIRV.CN's P/E ratio is 7.00. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to NIRV.CN's ROE of +0.26%. Regarding short-term risk, CYBN.NE is more volatile compared to NIRV.CN. This indicates potentially higher risk in terms of short-term price fluctuations for CYBN.NE.Check NIRV.CN's competition here
CYBN.NE vs WBIO.CN Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, WBIO.CN has a market cap of 324.8K. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while WBIO.CN trades at CA$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas WBIO.CN's P/E ratio is -3.50. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to WBIO.CN's ROE of +0.15%. Regarding short-term risk, CYBN.NE is more volatile compared to WBIO.CN. This indicates potentially higher risk in terms of short-term price fluctuations for CYBN.NE.Check WBIO.CN's competition here
CYBN.NE vs NSHS.CN Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, NSHS.CN has a market cap of 205.5K. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while NSHS.CN trades at CA$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas NSHS.CN's P/E ratio is 0.50. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to NSHS.CN's ROE of -0.22%. Regarding short-term risk, CYBN.NE is more volatile compared to NSHS.CN. This indicates potentially higher risk in terms of short-term price fluctuations for CYBN.NE.Check NSHS.CN's competition here
CYBN.NE vs NOVA.CN Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, NOVA.CN has a market cap of 148.3K. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while NOVA.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas NOVA.CN's P/E ratio is -0.05. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to NOVA.CN's ROE of +3.18%. Regarding short-term risk, CYBN.NE is more volatile compared to NOVA.CN. This indicates potentially higher risk in terms of short-term price fluctuations for CYBN.NE.Check NOVA.CN's competition here
CYBN.NE vs TRIL.TO Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, TRIL.TO has a market cap of 0. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while TRIL.TO trades at CA$23.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas TRIL.TO's P/E ratio is -34.06. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to TRIL.TO's ROE of -0.43%. Regarding short-term risk, CYBN.NE is more volatile compared to TRIL.TO. This indicates potentially higher risk in terms of short-term price fluctuations for CYBN.NE.Check TRIL.TO's competition here
CYBN.NE vs IN.TO Comparison April 2026
CYBN.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYBN.NE stands at 145.5M. In comparison, IN.TO has a market cap of 0. Regarding current trading prices, CYBN.NE is priced at CA$6.05, while IN.TO trades at CA$4.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYBN.NE currently has a P/E ratio of -1.16, whereas IN.TO's P/E ratio is -2.77. In terms of profitability, CYBN.NE's ROE is -0.61%, compared to IN.TO's ROE of -1.25%. Regarding short-term risk, CYBN.NE is more volatile compared to IN.TO. This indicates potentially higher risk in terms of short-term price fluctuations for CYBN.NE.Check IN.TO's competition here